Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
NCT04065555Phase 1Completed
- Sponsor
- Presage Biosciences
- Start
- Oct 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of subasumstat in head and neck cancer (HNC), sponsored by Presage Biosciences. Primary endpoint: Quantification of Cell Death and Immune Cell Biomarkers by Immunohistochemistry (IHC) and In-Situ Hybridization (ISH) in Resected Tissue at 3 days. Started Oct 2020; status: completed.
02
Drugs
subasumstat
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT04065555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065555.